In Setback, FDA Asks Epigenomics For More Data To Support Colon Cancer Test
This article was originally published in The Gray Sheet
Executive Summary
The diagnostics firm received a “not-approvable” letter for its Epi proColon blood test asking for data to support that the test actually increases patient compliance to colon cancer screening.